Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progestogen for preventing miscarriage.

R M Oates-Whitehead1, D M Haas, J A K Carrier

  • 1Research Division, Royal College of Paediatrics, 50 Hallam Street, London, UK, W1W 6DE.

The Cochrane Database of Systematic Reviews
|October 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiometabolic health after first pregnancy: Associations with social determinants of health. A nuMoM2b-HHS study.

American heart journal plus : cardiology research and practice·2023
Same author

Do we have an effective treatment for threatened miscarriage?

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

The quest for optimal labour induction drug delivery.

BJOG : an international journal of obstetrics and gynaecology·2019
Same author

The importance of cost considerations in preterm birth trials.

BJOG : an international journal of obstetrics and gynaecology·2019
Same author

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.

Clinical pharmacology and therapeutics·2016
Same author

Chronic villitis of unknown etiology and massive chronic intervillositis have similar immune cell composition.

Placenta·2015
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Progestogen use does not significantly prevent miscarriage in general. However, for women with recurrent miscarriages, progestogen therapy shows a significant decrease in miscarriage rates with no increased adverse effects for mother or baby.

Area of Science:

  • Reproductive Endocrinology
  • Obstetrics and Gynecology
  • Clinical Pharmacology

Background:

  • Progesterone is crucial for uterine receptivity and successful implantation.
  • Inadequate progestogen secretion is a suspected cause of miscarriage.
  • Progestational agents are used to prevent spontaneous miscarriage.

Purpose of the Study:

  • To evaluate the efficacy and safety of progestogens for miscarriage prevention.
  • To analyze data from randomized controlled trials on progestogen therapy.

Main Methods:

  • Systematic review and meta-analysis of 14 randomized controlled trials (1988 women).
  • Searched multiple databases up to April 2003.
  • Used Peto odds ratio for dichotomous outcomes.

Related Experiment Videos

Main Results:

  • No significant difference in miscarriage risk for the general population (OR 1.05, 95% CI 0.83-1.34).
  • Significant reduction in miscarriage rates for women with recurrent miscarriages (OR 0.39, 95% CI 0.17-0.91).
  • No significant difference in adverse effects for mother or baby across administration routes.

Conclusions:

  • Routine progestogen use is not supported for general miscarriage prevention.
  • Further trials are warranted for recurrent miscarriage cases.
  • Progestogen therapy shows promise for recurrent miscarriage without increased harm.